New hope for tough colorectal cancer: experimental drug combo enters human testing
NCT ID NCT06102902
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing whether adding an experimental drug called ZEN003694 to two approved cancer drugs (cetuximab and encorafenib) can help patients with a specific type of advanced colorectal cancer that has not responded to prior treatments. The study involves 30 adults whose cancer has spread and carries a BRAF V600E mutation. The main goals are to find the safest dose and check for side effects, while also looking at how long patients live without the cancer getting worse.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ZEN003694 (a BET protein inhibitor) combined with cetuximab and encorafenib
What this could lead to
If it works, this could offer a new treatment option for patients with a hard-to-treat form of colorectal cancer that has stopped responding to standard therapies.
What could go wrong
This is a very early phase 1 trial with only 30 participants, so it is primarily testing safety and dosing. The combination may cause significant side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Los Angeles General Medical Center
Los Angeles, California, 90033, United States
-
Ochsner Medical Center Jefferson
New Orleans, Louisiana, 70121, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California, 92868, United States
-
UCHealth University of Colorado Hospital
Aurora, Colorado, 80045, United States
-
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, California, 92612, United States
-
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
UT MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of Kansas Cancer Center
Kansas City, Kansas, 66160, United States
-
University of Kansas Clinical Research Center
Fairway, Kansas, 66205, United States
-
University of Kansas Hospital-Indian Creek Campus
Overland Park, Kansas, 66211, United States
-
University of Kansas Hospital-Westwood Cancer Center
Westwood, Kansas, 66205, United States
-
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104, United States
-
University of Virginia Cancer Center
Charlottesville, Virginia, 22908, United States
-
VCU Massey Comprehensive Cancer Center
Richmond, Virginia, 23298, United States